Print

Lantheus Medical Imaging Announces Promotion of Cyrille Villeneuve to Chief Commercial Officer and Dana Washburn, M.D. to Chief Medical Officer  
9/29/2011 2:29:13 PM

No. BILLERICA, Mass. (September 28, 2011) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the promotion of Cyrille Villeneuve to Chief Commercial Officer and Dana Washburn, M.D. to Chief Medical Officer.

Cyrille Villeneuve — Chief Commercial Officer

Mr. Villeneuve was most recently Vice President and General Manager, International. In his new role, Mr. Villeneuve will direct the Company’s global commercial strategy, which includes providing leadership for U.S. Sales and Marketing in addition to the Company’s international business units. Mr. Villeneuve will continue to report to Don Kiepert, Lantheus President and Chief Executive Officer.

“Throughout his tenure with the Company, Cyrille’s contributions have been critical in growing our international business and achieving consistently strong financial performance,” said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging. “Now, as Chief Commercial Officer, Cyrille’s strong leadership and oversight will drive the development, alignment and successful execution of our global commercial strategy.”

Mr. Villeneuve has served Lantheus Medical Imaging and its predecessors for more than 25 years, including as General Manager for the Company’s operations in Canada, Latin America and the Pacific Rim. Prior to joining Lantheus in 1985, Mr. Villeneuve held positions at the Montreal Heart Institute and Hospital Hotel-Dieu Montreal. Mr. Villeneuve earned a B.A. from Montreal University and a Master’s degree in Public Administration from École Nationale d’Administration Publique.

Dana Washburn — Chief Medical Officer

Dr. Washburn joined Lantheus in 2010 as Vice President, Clinical Development and Medical Affairs. In his new role as Chief Medical Officer, Dr. Washburn will lead Clinical Development, Medical Affairs, and Regulatory Affairs for the Company. Dr. Washburn will continue to report to Don Kiepert.

“Dana has broad experience in cardiovascular clinical care, cardiac imaging, and clinical development,” stated Kiepert. “In the short time that Dana has been with the Company, his knowledge, leadership and expertise have been exceptional in advancing our clinical programs. Dana has made a significant impact on our flurpiridaz F 18 development program, which entered into a Phase 3 clinical trial in June. His deep industry experience and work as a practicing nuclear cardiologist make him ideal for our new position of Chief Medical Officer.”

Dr. Washburn brings to the Company more than 15 years of leadership experience in cardiology, medical devices and diagnostics. Before joining Lantheus, he was Vice President, Clinical Trials and Safety, and Medical Safety Officer at Boston Scientific Corporation. Prior to his eight-year tenure at Boston Scientific, Dr. Washburn was a Cardiologist at the Framingham Heart Center and also served as Assistant Director of the Cardiovascular Hemodynamic and Imaging Laboratory at Tufts-New England Medical Center. Dr. Washburn holds an M.D. from the University of Massachusetts Medical School and is a Fellow of the American College of Cardiology.

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in discovering, developing and commercializing innovative diagnostic imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com

CONTACTS:

Lantheus Medical Imaging

Linda Lennox

978-671-8854

Meara Murphy

978-671-8508

Pure Communications

Michele Rozen

617-730-8284


//-->